ALEC
Price
$2.74Alerts
Change
+$0.21 (+8.30%)
Updated
Nov 11, 03:09 PM (EDT)
Capitalization
255.69M
111 days until earnings call
Intraday BUY SELL Signals
LYEL
Price
$17.09Alerts
Change
+$0.34 (+2.03%)
Updated
Nov 11, 03:21 PM (EDT)
Capitalization
364.15M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALEC vs LYEL

ALEC vs LYEL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALEC vs. LYEL commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a Buy and LYEL is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALEC with price predictions
Nov 10, 2026

ALEC's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ALEC turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 77 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +10.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 218 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.498). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for LYEL with price predictions
Nov 10, 2026

LYEL in upward trend: 10-day moving average broke above 50-day moving average on November 04, 2026

The 10-day moving average for LYEL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LYEL as a result. In 77 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on October 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.

LYEL moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +12.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in 200 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

LYEL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LYEL entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LYEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.557) is normal, around the industry mean (3.498). P/E Ratio (-1.171) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALEC: Fundamental Ratings
ALEC
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
93
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALECLYEL
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (ALEC: $2.53 vs. LYEL: $16.75)
Brand notoriety: ALEC and LYEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALEC: 90% vs. LYEL: 122%
Market capitalization -- ALEC: $255.69M vs. LYEL: $364.15M
ALEC [@Biotechnology] is valued at $255.69M. LYEL’s [@Biotechnology] market capitalization is $364.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALEC’s FA Score shows that 1 FA rating(s) are green while LYEL’s FA Score has 0 green FA rating(s).

  • ALEC’s FA Score: 1 green, 4 red.
  • LYEL’s FA Score: 0 green, 5 red.
According to our system of comparison, ALEC is a better buy in the long-term than LYEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALEC’s TA Score shows that 5 TA indicator(s) are bullish while LYEL’s TA Score has 5 bullish TA indicator(s).

  • ALEC’s TA Score: 5 bullish, 4 bearish.
  • LYEL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ALEC is a better buy in the short-term than LYEL.

Price Growth

ALEC (@Biotechnology) experienced а +23.41% price change this week, while LYEL (@Biotechnology) price change was +55.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.

Reported Earning Dates

ALEC is expected to report earnings on Mar 02, 2027.

LYEL is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ALEC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALEC has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALEC jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALEC
1D Price
Change %
ALEC100%
+2.85%
EDIT - ALEC
49%
Loosely correlated
-8.91%
BCYC - ALEC
46%
Loosely correlated
-2.12%
VYGR - ALEC
43%
Loosely correlated
-8.29%
ARVN - ALEC
43%
Loosely correlated
+2.37%
SANA - ALEC
42%
Loosely correlated
-1.42%
More

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+8.63%
VCYT - LYEL
46%
Loosely correlated
-7.18%
RYTM - LYEL
44%
Loosely correlated
+0.01%
SLDB - LYEL
44%
Loosely correlated
+2.14%
TSHA - LYEL
43%
Loosely correlated
-2.17%
ALEC - LYEL
42%
Loosely correlated
+2.85%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NUDG62.93N/A
N/A
Nuveen Dividend Growth Fund ETF (NUDG)
PBFR31.19-0.09
-0.29%
PGIM Laddered S&P 500 Buffer 20 ETF (PBFR)
CVLC93.00-0.37
-0.40%
Calvert US Large-Cap Core Responsible Index ETF (CVLC)
IEMG73.77-0.50
-0.67%
iShares Core MSCI Emerging Markets ETF (IEMG)
TSEL25.96-0.32
-1.23%
Touchstone Sands Capital US Select Growth ETF (TSEL)